antimycobacterial

Dapsone (Sulphadione) has activity against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae.

Sulfamoxole (Sulfamoxol) is an antibacterial belonging to sulfonamide.

1.(-)-Licarin B (Licarine B) has anti-mycobacterial activity.

Evocarpine shows antimycobacterial, and vasorelaxant effects, it can inhibit Ca2+ influx through voltage-dependent calcium channels.

Methyl caffeate (Methyl caffeate acid) acid

Azadiradione (AZD) (AZD) from the methanolic extract of seeds of Azadirachta indica

Antimycobacterial agent-4 (4-nitro-N-[4-(2-pyridyl)thiazol-2-yl]benzamide) has antibacterial activity against Mycobacterium tuberculosis.

Antimycobacterial agent-10 (compound 5) is an inhibitor of DNA gyrase with an IC50 of 96 nM against Mycobacterium tuberculosis gyrase, demonstrating antibacterial properties.

Antimycobacterial agent-11 (Compound QM7) is a bacteriostatic compound with anti-tuberculosis properties, exhibiting a minimum inhibitory concentration (MIC) of 5.58 μg/mL against Mycobacterium tuberculosis (Mtb). This agent is applicable in the field of anti-infective research, particularly for studies focusing on tuberculosis.

Antimycobacterial agent-7 (compound 4) is a 1,2,4-triazole antimycobacterial agent with a minimum inhibitory concentration (MIC) of 2 μg/mL. It inhibits Mtb KatG and induces the accumulation of reactive oxygen species (ROS) within Mtb cells, leading to oxidative damage and ultimately causing Mtb cell death.

Antimycobacterial agent-5 (compound 27) is an imidazopyridine amide compound that targets the Mycobacterium electron transport chain (ETC) respiratory CIII2CIV2 supercomplex. It acts on Mycobacterium smegmatis CIII2CIV2 with an IC50 of 441 nM.

Antimycobacterial agent-12 (Compound Ec42) is a Platensimycin derivative and acts as a dual inhibitor of KasA and KasB. It demonstrates minimum inhibitory concentrations (MIC) of 2 μg/mL against Staphylococcus aureus ATCC 29213, 2 μg/mL against Mycobacterium smegmatis, and 4 μg/mL against its isoniazid-resistant strains. In a Mycobacterium smegmatis-infected mouse model, Antimycobacterial agent-12 exhibits excellent antimycobacterial activity, making it a valuable tool for tuberculosis research.

Antimycobacterial agent-14 (compound 20s) is a potent antimycobacterial agent against Mycobacterium tuberculosis (M.tb) H37Ra strain, with a minimum inhibitory concentration (MIC) of 11.37 μM. This compound is applicable in tuberculosis (TB) research.

Antimycobacterial agent-15 (Compound 55) is a highly selective agent against Mycobacterium tuberculosis, demonstrating a MIC99 of 8 μM against MtbH37Rv. It shows significant efficacy against multidrug-resistant and extensively drug-resistant strains. Antimycobacterial agent-15 is applicable for tuberculosis research.

Antimycobacterial agent-1 (compound 33) demonstrates potent antimycobacterial activity against Mycobacterium tuberculosis H37Ra, with a minimal inhibitory concentration (MIC) value of 1 μg/ml, and exhibits low cytotoxicity in normal cells, as evidenced by an IC50 value of 143.2 μg/ml in Vero cells [1].

Antimycobacterial agent-2 is an effective anti-mycobacterial agent with a MIC99 of 0.8 μM against Mycobacterium tuberculosis (M.tb) H37Rv. Antimycobacterial agent-2 is cytotoxic, acting on CHO cells (IC50: 48.1 μM).

Antimycobacterial agent-3 is an antimycobacterial agent with low cytotoxicity. antimycobacterial agent-3 is effective against sensitive MTB strain H37Rv and resistant clinical isolates (MIC < 0.029-0.110 μ M).

Antimycobacterial agent-6 (compound 25) effectively inhibits Mycobacterium tuberculosis, including wild-type and fluoroquinolone-resistant strains, by targeting the Mtb DprE1-C387S mutant, with minimal inhibitory concentrations (MIC90) of 0.9 μM for H37Rv and MoxR strains, and 0.5 μM for the DprE1-P116S strain [1].

Antimycobacterial agent-8 (Compound 49) acts as an inhibitor of DNA gyrase (DNA gyrase). It exhibits antibacterial activity, with MIC90 values of 2.5 μM for Mycobacterium tuberculosis and 0.63 μM for M. abscessus. Additionally, Antimycobacterial agent-8 demonstrates effective plasma protein binding in mice.

Linaroside exhibited 30% inhibition for antimycobacterial activity against Mycobacterium tuberculosis, strain H(37)Rv at 6.25 microg mL(-1) concentration.

Ethambutol dihydrochloride is an anti-mycobacterial compound that inhibits arabinosyl transferase activity to prevent cell wall formation and can be used to induce hyperuricemia models.

Pyrazinamide (Pyrazinecarboxamide), an antimycobacterial, is utilized therapeutically as an antitubercular agent, which is a synthetic pyrazinoic acid amide derivative.

Rifabutin (LM-427) inhibits bacterial DNA-dependent RNA polymerase, thereby suppressing the initiation of RNA formation and leading to inhibition of RNA synthesis and transcription. Rifabutin is a semisynthetic ansamycin antibiotic with potent antimycobacterial properties.

Ferulenol, a sesquiterpene prenylated coumarin derivative, demonstrates potent antimycobacterial activity and [haemorrhagic] action by selectively targeting succinate ubiquinone reductase within the ubiquinone cycle.